Amal: Party of two

Amal's dual action cancer vaccines stimulate cell killing and memory responses

Amal Therapeutics S.A. is developing a platform of recombinant cancer vaccines that may induce a more potent and durable response than earlier vaccines by activating two different cell types important in antitumor immunity and by targeting multiple antigens.

Cancer vaccines induce dendritic cells to stimulate antigen-specific responses from CD4+ or CD8+ T cells, depending on the epitope used and the delivery construct.

When viral vector vaccines enter dendritic cells, their encoded antigens are processed and presented on MHC class I molecules, which induce the creation

Read the full 836 word article

How to gain access

Continue reading with a
two-week free trial.